Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium

Acta Histochemica

Volumn 111, Issue 4, 2009, Pages 350-360

  Mylonas, Ioannis ^a   Makovitzky, Josef ^b   Friese, Klaus ^a   Jeschke, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Endometrial cancer; Endometrium; Estrogen receptor (ER); Immunohistochemistry; Progesterone receptor (PR); Steroid receptors

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CONFORMATIONAL TRANSITION; ENDOMETRIUM CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; OSTEOPOROSIS; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 67349106712     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2008.11.012     Document Type: Review

References (106)

1. Alsbach G.P., Franck E.R., Poortman J., and Thijssen J.H. Subcellular distribution of estradiol and estrone in human endometrium and myometrium during the menstrual cycle. Contraception 27 (1983) 409-421
2. Ballare C., Uhrig M., Bechtold T., Sancho E., Di Domenico M., Migliaccio A., et al. Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23 (2003) 1994-2008
3. Balmer N.N., Richer J.K., Spoelstra N.S., Torkko K.C., Lyle P.L., and Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol 19 (2006) 1593-1605
4. Beekman J.M., Allan G.F., Tsai S.Y., Tsai M.J., and O'Malley B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol 7 (1993) 1266-1274
5. Carcangiu M.L., Chambers J.T., Voynick I.M., Pirro M., and Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: clinical and histologic correlations. Am J Clin Pathol 94 (1990) 247-254
6. Chambers J.T., MacLusky N., Eisenfield A., Kohorn E.I., Lawrence R., and Schwartz P.E. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 31 (1988) 65-81
7. Chambers J.T., Carcangiu M.L., Voynick I.M., and Schwartz P.E. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 94 (1990) 255-260
8. Couse J.F., Curtis Hewitt S., and Korach K.S. Receptor null mice reveal contrasting roles for estrogen receptor alpha and beta in reproductive tissues. J Steroid Biochem Mol Biol 74 (2000) 287-296
9. Creasman W.T. Prognostic significance of hormone receptors in endometrial cancer. Cancer 71 (1993) 1467-1470
10. Creasman W.T. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 24 (1997) S1-140-S141-150
11. Critchley H.O., Henderson T.A., Kelly R.W., Scobie G.S., Evans L.R., Groome N.P., et al. Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 87 (2002) 5265-5273
12. Dai D., Wolf D.M., Litman E.S., White M.J., and Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62 (2002) 881-886
13. Davies M.P., O'Neill P.A., Innes H., Sibson D.R., Prime W., Holcombe C., et al. Correlation of mRNA for oestrogen receptor beta splice variants ERbeta1, ERbeta2/ERbetacx and ERbeta5 with outcome in endocrine-treated breast cancer. J Mol Endocrinol 33 (2004) 773-782
14. De Vivo I., Huggins G.S., Hankinson S.E., Lescault P.J., Boezen M., Colditz G.A., et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 99 (2002) 12263-12268
15. Edwards D.P., Wardell S.E., and Boonyaratanakornkit V. Progesterone receptor interacting coregulatory proteins and cross talk with cell signaling pathways. J Steroid Biochem Mol Biol 83 (2002) 173-186
16. Ehrlich C.E., Young P.C., Stehman F.B., Sutton G.P., and Alford W.M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158 (1988) 796-807
17. Fujimoto J., Sakaguchi H., Aoki I., Toyoki H., and Tamaya T. Clinical implications of the expression of estrogen receptor-alpha and -beta in primary and metastatic lesions of uterine endometrial cancers. Oncology 62 (2002) 269-277
18. Fujishita A., Nakane P.K., Koji T., Masuzaki H., Chavez R.O., Yamabe T., et al. Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril 67 (1997) 856-864
19. Fukuda K., Mori M., Uchiyama M., Iwai K., Iwasaka T., and Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 69 (1998) 220-225
20. Gadkar-Sable S., Shah C., Rosario G., Sachdeva G., and Puri C. Progesterone receptors: various forms and functions in reproductive tissues. Front Biosci 10 (2005) 2118-2130
21. Garcia E., Bouchard P., De Brux J., Berdah J., Frydman R., Schaison G., et al. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating. J Clin Endocrinol Metab 67 (1988) 80-87
22. Gehrig P.A., Van Le L., Olatidoye B., and Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 86 (1999) 2083-2089
23. Geisinger K.R., Homesley H.D., Morgan T.M., Kute T.E., and Marshall R.B. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 58 (1986) 1518-1525
24. Graham J.D., and Clarke C.L. Expression and transcriptional activity of progesterone receptor A and progesterone receptor B in mammalian cells. Breast Cancer Res 4 (2002) 187-190
25. Graham J.D., Yeates C., Balleine R.L., Harvey S.S., Milliken J.S., Bilous A.M., et al. Characterization of progesterone receptor A and B expression in human breast cancer. Cancer Res 55 (1995) 5063-5068
26. Greene G.L., Fitch F.W., and Jensen E.V. Monoclonal antibodies to estrophilin: probes for the study of estrogen receptor. Proc Natl Acad Sci USA 77 (1980) 157-161
27. Gronemeyer H. Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 25 (1991) 89-123
28. Guiochon-Mantel A., Lescop P., Christin-Maitre S., Loosfelt H., Perrot-Applanat M., and Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J 10 (1991) 3851-3859
29. Han S.J., DeMayo F.J., Xu J., Tsai S.Y., Tsai M.J., and O'Malley B.W. Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol Endocrinol 20 (2006) 45-55
30. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (1999) 1474-1481
31. Herynk M.H., and Fuqua S.A. Estrogen receptor mutations in human disease. Endocr Rev 25 (2004) 869-898
32. Horvath G., Leser G., Hahlin M., and Henriksson M. Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 10 (2000) 128-136
33. Horwitz K.B., Mockus M.B., Pike A.W., Fennessey P.V., and Sheridan R.L. Progesterone receptor replenishment in T47D human breast cancer cells. Roles of protein synthesis and hormone metabolism. J Biol Chem 258 (1983) 7603-7610
34. Horwitz K.B., Tung L., and Takimoto G.S. Novel mechanisms of antiprogestin action. J Steroid Biochem Mol Biol 53 (1995) 9-17
35. Jacobsen B.M., Schittone S.A., Richer J.K., and Horwitz K.B. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19 (2005) 574-587
36. Jazaeri O., Shupnik M.A., Jazaeri A.A., and Rice L.W. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol 74 (1999) 38-47
37. Jereczek-Fossa B., Badzio A., and Jassem J. Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer 9 (1999) 285-294
38. Jones R.K., Bulmer J.N., and Searle R.F. Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod 10 (1995) 3272-3279
39. Jordan V.C. Estrogen receptor as a target for the prevention of breast cancer. J Lab Clin Med 133 (1999) 408-414
40. Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell 5 (2004) 207-213
41. Jordan V.C., and Brodie A.M. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 72 (2007) 7-25
42. Kadar N., Malfetano J.H., and Homesley H.D. Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 50 (1993) 281-286
43. Kampa M., and Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol 246 (2006) 76-82
44. King W.J., and Greene G.L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307 (1984) 745-747
45. Kleine W., Maier T., Geyer H., and Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 38 (1990) 59-65
46. Koehler K.F., Helguero L.A., Haldosen L.A., Warner M., and Gustafsson J.A. Reflections on the discovery and significance of estrogen receptor beta. Endocr Rev 26 (2005) 465-478
47. Krett N.L., Wei L.L., Francis M.D., Nordeen S.K., Gordon D.F., Wood W.M., et al. Human progesterone A-receptors can be synthesized intracellularly and are biologically functional. Biochem Biophys Res Commun 157 (1988) 278-285
48. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 (1997) 863-870
49. Kuiper G.G., Shughrue P.J., Merchenthaler I., and Gustafsson J.A. The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol 19 (1998) 253-286
50. Kumar N.S., Richer J., Owen G., Litman E., Horwitz K.B., and Leslie K.K. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 58 (1998) 1860-1865
51. Lecce G., Meduri G., Ancelin M., Bergeron C., and Perrot-Applanat M. Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 86 (2001) 1379-1386
52. Lemieux P., and Page M. Production and characterization of monoclonal antibodies against a human ovarian teratocarcinoma cell line. Anticancer Res 14 (1994) 2709-2715
53. Leslie K.K., Kumar N.S., Richer J., Owen G., Takimoto G., Horwitz K.B., et al. Differential expression of the A and B isoforms of progesterone receptor in human endometrial cancer cells. Only progesterone receptor B is induced by estrogen and associated with strong transcriptional activation. Ann N Y Acad Sci 828 (1997) 17-26
54. Lessey B.A., Killam A.P., Metzger D.A., Haney A.F., Greene G.L., and McCarty Jr. K.S. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab 67 (1988) 334-340
55. Lukes A.S., Kohler M.F., Pieper C.F., Kerns B.J., Bentley R., Rodriguez G.C., et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73 (1994) 2380-2385
56. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery Jr. C.A., et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9 (1995) 2266-2278
57. Mangal R.K., Wiehle R.D., Poindexter III A.N., and Weigel N.L. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol 63 (1997) 195-202
58. Marshburn P.B., Zhang J., Bahrani-Mostafavi Z., Mostafavi B.Z., Marroum M.C., Mougeot J.L., et al. Estrogen receptor-alpha messenger RNA variants that lack exon 5 or exon 7 are coexpressed with wild-type form in human endometrium during all phases of the menstrual cycle. Am J Obstet Gynecol 191 (2004) 626-633 [discussion 633-624]
59. Matsuzaki S., Fukaya T., Suzuki T., Murakami T., Sasano H., and Yajima A. Oestrogen receptor alpha and beta mRNA expression in human endometrium throughout the menstrual cycle. Mol Hum Reprod 5 (1999) 559-564
60. Matthews J., Wihlen B., Tujague M., Wan J., Strom A., and Gustafsson J.A. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20 (2006) 534-543
61. Mendelson C.R., and Hardy D.B. Role of the progesterone receptor (PR) in the regulation of inflammatory response pathways and aromatase in the breast. J Steroid Biochem Mol Biol 102 (2006) 241-249
62. Miyamoto T., Watanabe J., Hata H., Jobo T., Kawaguchi M., Hattori M., et al. Significance of progesterone receptor-A and -B expressions in endometrial adenocarcinoma. J Steroid Biochem Mol Biol 92 (2004) 111-118
63. Mohsin S.K., Weiss H., Havighurst T., Clark G.M., Berardo M., Roanh le D., et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 17 (2004) 1545-1554
64. Montano M.M., Ekena K., Delage-Mourroux R., Chang W., Martini P., and Katzenellenbogen B.S. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci USA 96 (1999) 6947-6952
65. Moriarty K., Kim K.H., and Bender J.R. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology 147 (2006) 5557-5563
66. Morris P.C., Anderson J.R., Anderson B., and Buller R.E. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 56 (1995) 406-411
67. Mote P.A., Johnston J.F., Manninen T., Tuohimaa P., and Clarke C.L. Detection of progesterone receptor forms A and B by immunohistochemical analysis. J Clin Pathol 54 (2001) 624-630
68. Moy B., and Goss P.E. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches. Clin Cancer Res 12 (2006) 4790-4793
69. Mukherjee A., Soyal S.M., Fernandez-Valdivia R., Gehin M., Chambon P., Demayo F.J., et al. Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol Cell Biol 26 (2006) 6571-6583
70. Mulac-Jericevic B., Mullinax R.A., DeMayo F.J., Lydon J.P., and Conneely O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289 (2000) 1751-1754
71. Mylonas I., Speer R., Makovitzky J., Richter D.U., Briese V., Jeschke U., et al. Immunohistochemical analysis of steroid receptors and glycodelin A (PP14) in isolated glandular epithelial cells of normal human endometrium. Histochem Cell Biol 114 (2000) 405-411
72. Mylonas I., Jeschke U., Makovitzky J., Winkler L., Richter D.U., Friese K., et al. Immunohistochemical expression of steroid receptors and glycodelin A in isolated proliferative human endometrial glandular cells after stimulation with tamoxifen and phytoestrogens (genistein and daidzein). Anticancer Res 23 (2003) 1119-1125
73. Mylonas I., Jeschke U., Shabani N., Kuhn C., Balle A., Kriegel S., et al. Immunohistochemical analysis of estrogen receptor alpha, estrogen receptor beta and progesterone receptor in normal human endometrium. Acta Histochem 106 (2004) 245-252
74. Mylonas I., Jeschke U., Shabani N., Kuhn C., Kriegel S., Kupka M.S., et al. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR). Anticancer Res 25 (2005) 1679-1686
75. Mylonas I., Jeschke U., Shabani N., Kuhn C., Kunze S., Dian D., et al. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium. Histol Histopathol 22 (2007) 169-176
76. Nyholm H.C., Christensen I.J., and Nielsen A.L. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 59 (1995) 347-351
77. Oehler M.K., Brand A., and Wain G.V. Molecular genetics and endometrial cancer. J Br Menopause Soc 9 (2003) 27-31
78. Oreskovic S., Babic D., Kalafatic D., Barisic D., and Beketic-Oreskovic L. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma. Gynecol Oncol 93 (2004) 34-40
79. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
80. Palmer D.C., Muir I.M., Alexander A.I., Cauchi M., Bennett R.C., and Quinn M.A. The prognostic importance of steroid receptors in endometrial carcinoma. Obstet Gynecol 72 (1988) 388-393
81. Pertschuk L.P., Masood S., Simone J., Feldman J.G., Fruchter R.G., Axiotis C.A., et al. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 63 (1996) 28-33
82. Quezada S., Avellaira C., Johnson M.C., Gabler F., Fuentes A., and Vega M. Evaluation of steroid receptors, coregulators, and molecules associated with uterine receptivity in secretory endometria from untreated women with polycystic ovary syndrome. Fertil Steril 85 (2006) 1017-1026
83. Rey J.M., Pujol P., Dechaud H., Edouard E., Hedon B., and Maudelonde T. Expression of oestrogen receptor-alpha splicing variants and oestrogen receptor-beta in endometrium of infertile patients. Mol Hum Reprod 4 (1998) 641-647
84. Sakaguchi H., Fujimoto J., Hong B.L., Nakagawa Y., and Tamaya T. Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol 93 (2004) 394-399
85. Sarvilinna N., Eronen H., Miettinen S., Vienonen A., and Ylikomi T. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. Int J Cancer (2005)
86. Savouret J.F., Chauchereau A., Misrahi M., Lescop P., Mantel A., Bailly A., et al. The progesterone receptor. Biological effects of progestins and antiprogestins. Hum Reprod 9 (1994) 7-11
87. Savouret J.F., Rauch M., Redeuilh G., Sar S., Chauchereau A., Woodruff K., et al. Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene. J Biol Chem 269 (1994) 28955-28962
88. Shabani N., Kuhn C., Kunze S., Schulze S., Mayr D., Dian D., et al. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43 (2007) 2434-2444
89. Shabani N., Mylonas I., Jeschke U., Thaqi A., Kuhn C., Puchner T., et al. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium. Anticancer Res 27 (2007) 2027-2033
90. Shemshedini L., Knauthe R., Sassone-Corsi P., Pornon A., and Gronemeyer H. Cell-specific inhibitory and stimulatory effects of Fos and Jun on transcription activation by nuclear receptors. EMBO J 10 (1991) 3839-3849
91. Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13 (2000) 295-308
92. Sivridis E., Giatromanolaki A., Koukourakis M., and Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 438 (2001) 470-477
93. Smith C.L., Htun H., Wolford R.G., and Hager G.L. Differential activity of progesterone and glucocorticoid receptors on mouse mammary tumor virus templates differing in chromatin structure. J Biol Chem 272 (1997) 14227-14235
94. Snijders M.P., de Goeij A.F., Debets-Te Baerts M.J., Rousch M.J., Koudstaal J., and Bosman F.T. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause. J Reprod Fertil 94 (1992) 363-371
95. Snijders M.P., de Goeij A.F., Koudstaal J., Thunnissen E.B., de Haan J., and Bosman F.T. Oestrogen and progesterone receptor immunocytochemistry in human hyperplastic and neoplastic endometrium. J Pathol 166 (1992) 171-177
96. Takama F., Kanuma T., Wang D., Kagami I., and Mizunuma H. Oestrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer. Br J Cancer 84 (2001) 545-549
97. Takimoto G.S., Tasset D.M., Eppert A.C., and Horwitz K.B. Hormone-induced progesterone receptor phosphorylation consists of sequential DNA-independent and DNA-dependent stages: analysis with zinc finger mutants and the progesterone antagonist ZK98299. Proc Natl Acad Sci USA 89 (1992) 3050-3054
98. Taylor A.H., Guzail M., Wahab M., Thompson J.R., and Al-Azzawi F. Quantitative histomorphometric analysis of gonadal steroid receptor distribution in the normal human endometrium through the menstrual cycle. Histochem Cell Biol 123 (2005) 463-474
99. Tora L., Gronemeyer H., Turcotte B., Gaub M.P., and Chambon P. The N-terminal region of the chicken progesterone receptor specifies target gene activation. Nature 333 (1988) 185-188
100. Tora L., White J., Brou C., Tasset D., Webster N., Scheer E., et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59 (1989) 477-487
101. Vecek N., Nola M., Marusic M., Ilic J., Babic D., Petrovecki M., et al. Prognostic value of steroid hormone receptors concentration in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 73 (1994) 730-733
102. Vegeto E., Shahbaz M.M., Wen D.X., Goldman M.E., O'Malley B.W., and McDonnell D.P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7 (1993) 1244-1255
103. Wang H., Critchley H.O., Kelly R.W., Shen D., and Baird D.T. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod 4 (1998) 407-412
104. Webb P., Lopez G.N., Uht R.M., and Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 9 (1995) 443-456
105. Webb P., Nguyen P., and Kushner P.J. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J Biol Chem 278 (2003) 6912-6920
106. Welshons W.V., Lieberman M.E., and Gorski J. Nuclear localization of unoccupied oestrogen receptor. Nature 307 (1984) 747-749